BK Virus Nephropathy: Reduction Alone or an Adjunct
No antiviral has ever been proven to work against BK virus, which leaves immunosuppression reduction as the one treatment everyone agrees on — and a real, still-unsettled argument about whether a high enough viral load justifies reaching for more than that alone.
A.F. is thirty-nine, a paramedic who has spent most of his career being the person who shows up when something goes wrong for someone else, and who has never had much of a health story of his own to tell until this year. His deceased-donor kidney transplant, seven months ago, replaced native kidneys destroyed by a genetic condition diagnosed only after his function had already declined too far to intervene earlier — otherwise, aside from the transplant itself, his chart is close to empty.
Routine post-transplant surveillance caught his creatinine drifting upward over the past six weeks, from a stable 1.3 to 2.1, prompting a for-cause biopsy that came back with SV40 immunostaining positive across several tubules — biopsy-proven BK virus nephropathy, not rejection, not another process. His quantitative plasma BK PCR, drawn the same week, returned at 340,000 copies per milliliter, high enough that the team is weighing not just whether to reduce immunosuppression, which nobody disputes, but whether his viral load alone argues for adding something on top of that reduction rather than waiting through the weeks a reduction-alone taper typically takes to show effect.
He asks, almost reflexively, whether there's a specific antiviral for this the way there would be for a virus he'd recognize from his own ambulance runs — herpes, influenza, something with a named drug attached to it. There isn't, not a proven one, and that absence is part of what makes this decision harder than a typical post-transplant infection: the team isn't choosing between two antivirals of differing strength, it's deciding how much to trust withdrawal of his own immunosuppression to do work no drug has been shown to reliably do faster.
Transplant clinic, reviewing the biopsy
Reduce immunosuppression and hold there — stop the mycophenolate, lower the tacrolimus trough target — and reassess viral load in two to three weeks. No specific antiviral has ever been proven to work against BK, and most published cohorts describe clearance with reduction alone, without an added agent. Reaching for something unproven on top of an already-injured kidney adds real risk for a benefit nobody has demonstrated.
340,000 copies is a high starting point, and I don't think we should treat every BK nephropathy case as identical regardless of viral burden. IVIG carries real anti-BK neutralizing antibody content from pooled donor plasma, doesn't add nephrotoxicity the way some older adjuncts do, and the evidence for benefit, while still mostly retrospective, is growing specifically in higher-load cases like his. Waiting several weeks through a slow reduction-alone taper risks more graft injury accumulating before the viral load has a chance to fall.
I'm not disputing reduction is the necessary first step — I agree with that completely. I'm disputing that "necessary" means "sufficient" at a viral load this high, when we have an option that doesn't carry the toxicity tradeoff older adjuncts do.
Before this goes further, I want to head off the leflunomide question, since it's usually the next thing raised in cases like this. I want to be exact about the evidence rather than wave at it: one phase 2 randomized trial failed to support a leflunomide effect, and a systematic review of forty studies found that adding leflunomide or cidofovir to immunosuppression reduction did not meaningfully improve death-censored graft loss. Leca's work also showed that pushing to higher leflunomide levels bought hemolysis rather than better viral clearance. That is a thinner and more negative body of evidence than its popularity suggests, and it carries a real hepatotoxicity and hemolysis-monitoring burden. I wouldn't add it here.
IVIG's biological rationale is genuinely real, and I'm not dismissing it — but the evidence is still mostly case series, not a controlled trial. The randomized trial that would settle it, BEAT-BK, is enrolling now and comparing reduction with and without IVIG; we don't get to use its answer tonight. Rather than start it today, I'd set a concrete threshold now: reduce immunosuppression, recheck viral load in two weeks, and if it hasn't fallen by at least half, add IVIG at that point rather than either waiting indefinitely or starting it immediately on a single high number.
Agreed: mycophenolate discontinued, tacrolimus trough target lowered, and viral load rechecked in two weeks against a pre-specified threshold — IVIG added only if the load has not at least halved by then. The infectious disease physician's threshold framing was accepted by both other voices as a real middle ground between reduction alone and an immediate adjunct, and leflunomide was ruled out explicitly rather than left unaddressed.
Not agreed: whether the two-week recheck interval itself is the right window, given how fast his creatinine had already been rising before the biopsy. The pharmacist would prefer a one-week recheck given the starting viral load's severity; the physician thinks a shorter interval risks acting on noise rather than a real trend, since viral load can fluctuate meaningfully week to week even on an effective reduction regimen.